Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Hopes Esomeprazole Helps Make Private Label OTCs A Bright Spot

Executive Summary

The firm lowers its 2016 guidance as its European branded OTC drug and nutritional product business and its Rx topicals business appear to be major obstacles to escaping its earnings slump.


Related Content

Perrigo's Rx Business Looks Ready To Sell, Says Hedge Fund Investor
Perrigo Plays To OTC Strength With GoodSense Firm Acquisition
FDA New Drug Approval Count May Fall Back To Earth In 2016
Perrigo Out From Under VMS Weight As IVC Lifts Private Label Profile
Keeping Track: FDA Approval Activity Heats Up With Ocaliva, Zinbryta And More
Culture Shock In Europe For Perrigo With Branded Consumer Business
Private Label Mucinex March Reaches Two Formulations
Perrigo Navigates Earnings Storm Weathering Change At Helm


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts